The conversational diagnostic artificial intelligence system AMIE (Articulate Medical Intelligence Explorer) has potential as a real-world tool for clinical history-taking and diagnostic dialogue, based on its performance in simulated consultations.
Category: biotech/medical – Page 145
The mTOR Inhibitors Lifespan Project Enters Next Phase
Ora Biomedical, in partnership with Rapamycin Longevity Lab, announces the successful funding of the first subproject under its ambitious initiative to conduct a rapid lifespan analysis of 601 mTOR inhibitors in roundworms.
With $50,000 secured, Ora Biomedical will now commence the next phase of the first subproject. This will be a high-throughput screening of 301 mTOR inhibitors using its cutting-edge WormBot-AI technology. This milestone marks an important step toward identifying next-generation compounds that could be more effective than rapamycin, which is currently seen as the golden standard because of its good longevity effects in multiple species.
Mitchell Lee, CEO of Ora Biomedical, emphasized the importance of this research by stating: “The potential of targeting aging to broadly improve healthy lifespan is clear from decades of studies with compounds like rapamycin. However, even for well-validated molecular targets like mTOR, we still don’t know the best interventions. We at Ora Biomedical are proud to partner with Rapamycin Longevity Lab to advance our understanding around targeting mTOR and related kinases for maximizing healthy lifespan. None of this work is possible without support from visionary donors and organizations like the Lifespan Research Institute, the nonprofit behind Lifespan.io, with whom we have partnered to create pathways for donations to advance longevity science. To all those involved, thank you again, and we are excited to get to work!”
An at-home smell test could pave the way for early detection of Alzheimer’s disease
When it comes to early detection of cognitive impairment, a new study suggests that the nose knows. Researchers from Mass General Brigham have developed olfactory tests—in which participants sniff odor labels that have been placed on a card—to assess people’s ability to discriminate, identify and remember odors. They found that participants could successfully take the test at home and that older adults with cognitive impairment scored lower on the test than cognitively normal adults.
Results are published in Scientific Reports.
“Early detection of cognitive impairment could help us identify people who are at risk of Alzheimer’s disease and intervene years before memory symptoms begin,” said senior author Mark Albers, MD, Ph.D., of the Laboratory of Olfactory Neurotranslation, the McCance Center for Brain Health, and Department of Neurology at Massachusetts General Hospital.
Regulation of microbial gene expression: the key to understanding our gut microbiome
During the past two decades, gut microbiome studies have established the significant impact of the gut microbiota and its metabolites on host health. However, the molecular mechanisms governing the production of microbial metabolites in the gut environment remain insufficiently investigated and thus are poorly understood. Here, we propose that an enhanced understanding of gut microbial gene regulation, which is responsive to dietary components and gut environmental conditions, is needed in the research field and essential for our ability to effectively promote host health and prevent diseases through interventions targeting the gut microbiome.
Understanding disrupted motivation in Parkinson’s disease through a value-based decision-making lens
Neurobehavioural disturbances such as loss of motivation have profound effects on the lives of many people living with Parkinson’s disease (PD), as well as other brain disorders. The field of decision-making neuroscience, underpinned by a plethora of work across species, provides an important framework within which to investigate apathy in clinical populations. Here we review how changes in a number of different processes underlying value-based decision making may lead to the common phenotype of apathy in PD. The application of computational models to probe both behaviour and neurophysiology show promise in elucidating these cognitive processes crucial for motivated behaviour. However, observations from the clinical management of PD demand an expanded view of this relationship, which we aim to delineate. Ultimately, effective treatment of apathy may depend on identifying the pattern in which decision making and related mechanisms have been disrupted in individuals living with PD.
Abstract: How can we enhance the efficacy of CAR T cell therapy for HIV?
Anjie Zhen & team show rapamycin reduces HIV-mediated chronic inflammation and T cell exhaustion, delaying viral rebound and reducing viral reservoir in mice.
2UCLA AIDS Institute and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Lifespan-extending Drugs in Model Organisms and Humans | Dr Kevin Perez
Join us this episode as we explore how a cutting-edge, high-throughput screening platform can identify lifespan-extending compounds in diverse model organisms, with Dr Kevin Perez, co-founder of Epiterna and Junior Group Leader at Charité Universitätsmedizin Berlin, and host Prof Brian Kennedy, Director of the Centre for Healthy Longevity at #NUSMedicine.
Register for upcoming #HealthyLongevity #webinar sessions at https://nus-sg.zoom.us/webinar/register/2117367621680/WN_g5RF29EWQf65KDFfpVLjFA
Disclaimer: The opinions and advice expressed in this webinar are those of the speakers and do not represent the views and opinions of the organizers and National University of Singapore or any of its subsidiaries or affiliates. The information provided in this webinar is for general information purposes only as part of a general discussion on public health. The information is not intended to be a substitute for professional medical advice, diagnoses or treatment; and cannot be relied on in place of consultation with your licensed healthcare provider. All Rights Reserved.
All of the proceedings of this webinar, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved to the speaker or NUS. No statement or presentation made is to be regarded as dedicated to the public domain.
Any sound reproduction, transcript or other use of the material presented at this course without the permission of the speaker or NUS is prohibited to the full extent of common-law copyright in such material.
Revealing the largest wiring diagram and functional map of the brain
How does the brain work? Where, and when, and why do neurons connect and send their signals? Scientists have created the largest wiring diagram and functional map of an animal brain to date to learn more. Research teams at Allen Institute, @BCMweb and @princeton worked together to map half a billion synapses, over 200,000 cells, and 4km of axons from a cubic millimeter of mouse brain, providing unparalleled detail into its structure and functional properties. The project is part of the Machine Intelligence from Cortical Networks (MICrONS) program, which seeks to revolutionize machine learning by reverse-engineering the algorithms of the brain. Research findings reveal key insights into brain activity, connectivity, and structure—shedding light on both form and function—within a region of the mouse visual cortex that plays a critical role in brain health and is often disrupted in neurological conditions such as Alzheimer’s disease, autism, and addiction. These insights could revolutionize our ability to treat neuropsychiatric diseases or study the influence of drugs and other changes on the brain.
This extraordinary achievement begins to reveal the elusive language the brain uses to communicate amongst its millions of cells and the cortical mechanisms of intelligence—one of the holy grails of science.
Learn more about this research: https://alleninstitute.org/news/scien… open science data: https://www.microns-explorer.org/ Explore the publications in Nature: https://www.nature.com/immersive/d428… Follow us on social media: Bluesky — https://bsky.app/profile/alleninstitu… Facebook — / alleninstitute X —
/ alleninstitute Instagram —
/ alleninstitute LinkedIn —
/ allen-institute TikTok —
/ allen.institute.
Access open science data: https://www.microns-explorer.org/
Explore the publications in Nature: https://www.nature.com/immersive/d428…
Follow us on social media:
Bluesky — https://bsky.app/profile/alleninstitu…
Facebook — / alleninstitute.
X — / alleninstitute.
Instagram — / alleninstitute.
LinkedIn — / allen-institute.
TikTok — / allen.institute
Gamma Knife Radiosurgery for optic nerve sheath meningioma: comparison of efficacy and costs with radiotherapy under Korean health insurance system
To survey the real-world effectiveness and cost of optic nerve sheath meningioma (ONSM) treating with Gamma Knife Radiosurgery (GKRS), and compare with the external beam radiation therapy (EBRT).
Retrospective, comparative study that included patients with primary ONSM treated with either GKRS or EBRT in Samsung Medical Center, Korea. The treatment response, and treatment costs were compared between GKRS and EBRT groups.
There were 34 adult patients with primary ONSM treated with either GKRS (n = 25) or EBRT (n = 9) (follow-up period: 6–207 months). The local tumor control rates (GKRS: 92%; EBRT: 100%; P = 1) and vision preservation rates (GKRS: 64%; EBRT: 67%; P = 1) were similar in both groups. The mean gross tumor volume (GTV) decreased by 21.4 ± 19.7% after GKRS and 26.4 ± 18.7% after EBRT (P = 0.4803). The complication rates did not differ between two modalities. Factors associated with better visual outcomes were pretreatment BCVA 20/50 (odds ratio: 6.000, P = 0.0234) and the absence of intracranial tumor extension (odds ratio: 30.00, P = 0.0001). GKRS reduced the total costs of care by 43% under Korean National Health Insurance System (NHIS).